Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

Quince Therapeutics will host a virtual key opinion leader event on Monday, September 28, 2026, from 12:30-2:00 PM ET, focused on the current treatment landscape for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS). The event features PH-ILD experts Aaron B. Waxman (Brigham and Women's Hospital) and Paul Yu (Massachusetts General Hospital) plus BOS expert Steven Hays (UCSF Health), and will review LAM-001, the company's proprietary once-daily inhaled DPI formulation of rapamycin, an mTOR inhibitor in Phase 2 development.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.